DCA is known to inhibit all PDK isoforms at the mM range in vitro, with potency estimated to be higher against PDK2 < PDK 1 ≃ PDK4 < PDK3,36 and it has been shown that DCA treatment diminishes the phosphorylation of the three serine phosphorylation sites on PDH (PDHS232, PDHS293, and PDHS300) in different cancer cell lines. The gene discussed is PDK2; the disease is cancer.